Canada: Biosimilars In Canada: New Draft Guidelines From Health Canada

This article first appeared in Update, Issue 4, July/August 2009. Reprinted with permission of the Food and Drug Law Institute (FDLI) ©2009.

Health Canada announced that it had granted marketing authorization for Omnitrope (a human growth hormone), the first subsequent entry biologic (SEB) to be approved for sale in Canada. Much to the surprise of stakeholders, this April 22, 2009 announcement, occurred in the midst of a consultation period, during which Health Canada was actively seeking comments on a draft guidance document intended to establish an SEB regulatory pathway. Adding to the consternation of innovator biologic manufacturers, pending SEB submissions currently under review by Health Canada will likely be approved before the guidance document is finalized and certainly without any amendment to the current legislative scheme under the Food and Drug Regulations (Regulations).1

The original draft guidance document "Information and Submission Requirements for Subsequent Entry Biologics (SEBs)" (Original Guidance) was published by Health Canada on January 30, 2008, and was the subject of an earlier article published in Update.2 Th e Original Guidance has since been revised, and was released on March 27, 2009 (Revised Guidance). It is subject to a 60-day comment period that ended on May 26, 2009. Despite repeated submissions by innovators during the consultation following publication of the Original Guidance, the Revised Guidance states that SEB submissions will take place under the existing Regulations and without a legislative amendment to create a specific SEB approval pathway. Th e Revised Document, together with modifications to two other Health Canada guidance documents on patent and data protection, will establish the basis for an SEB approval pathway.3

What Are SEBs?

Biologics are a subset of drugs that are generated from biological sources and include gene therapies, vaccines, antibodies and other therapeutic products derived through biotechnology. Biologics are structurally complex and diffi cult to manufacture in comparison with traditional pharmaceuticals, which have a chemical entity as the active medicinal ingredient.

An SEB is defined by Health Canada as a biologic product that would enter the market subsequent to, and is similar to, an innovator product authorized for sale in Canada. Because the two products are "similar," non-clinical and clinical data generated using the innovator biologic, or "reference product," are relevant to the safety and efficacy of an SEB and may be relied upon to reduce the amount of data in an SEB submission.

In contrast to generic pharmaceuticals, where the active ingredient in a generic pharmaceutical is identical to that of a reference product or where the generic pharmaceutical is therapeutically equivalent to the reference product, "similar" in the biologic context does not imply that an SEB is identical to its reference product or that the two products are therapeutic equivalents.

Instead, by demonstrating similarity, an SEB manufacturer attempts to predict that any difference in quality attributes in relation to the reference product should have no adverse impact on the safety and efficacy of the SEB. Th us, the two key features in an SEB submission are 1) a comparison to a reference product, and 2) a reduced data requirement due to reliance on data previously generated for the reference product.

Regulatory Approval

The Revised Guidance indicates that SEBs will be approved through the existing New Drug Submission (NDS) pathway under the Regulations. It is noteworthy that the NDS provisions do not contemplate a manufacturer's reliance on a reference product. Further, it is questionable whether these provisions aford Health Canada the discretion to reduce the data requirements of an NDS in the manner contemplated by the Revised Guidance.

In fact, when an abbreviated data set is contemplated, as in the case for generic pharmaceutical drugs, the Regulations carve out a specific exception—the Abbreviated New Drug Submission (ANDS) pathway. Under the ANDS pathway, a generic pharmaceutical manufacturer may rely on the safety tests of a defined "Canadian reference product" by demonstrating that the generic drug is its pharmaceutical equivalent and bioequivalent. Th e ANDS pathway cannot support the approval of SEBs because an SEB is invariably not identical to a reference biologic product. Th e structure and manufacturing processes used for biologics call for a standard of "similarity" rather than "identicality."

Regardless of these inadequacies in the current regime with respect to biologics, Health Canada intends to use this framework as the basis for the approval of SEBs.

Data Set

The Revised Guidance provides some general information on the type of data that an SEB manufacturer must provide to Health Canada. As with a standard NDS, a full chemistry and manufacturing package is required to demonstrate similarity in the manufacturing processes. Comparative studies are also needed to show comparable physicochemical and immunochemical properties, biological activity and purity.

A final decision on similarity to a reference product will be largely based on analytical and biological characterization. Clinical and non-clinical tests are required to varying degrees depending upon the quantity and extent of demonstrated similarity between an SEB and a reference product. Th e Revised Guidance discusses the need for pharmacokinetic and pharmacodynamic studies, as well as comparative clinical trials to show similarity in efficacy and safety profiles, including immunogenicity.

Stipulations have been made with respect to the clinical indications for an SEB. An SEB will not automatically receive authorization for each of the indications for which the reference product is approved; rather, indications will depend upon the data provided by the sponsor. If, however, the mechanismof- action of an SEB strongly supports an indication, approval for that indication may be granted even in the absence of data.

Foreign Reference Product

Citing the small number of innovator biologics in Canada and the desire to provide flexibility to manufacturers, Health Canada will allow a manufacturer to use a non-Canadian reference product to demonstrate similarity between an SEB and a product authorized for sale in Canada. Th e Revised Guidance requires an SEB submission to contain sufficient evidence of the link between the foreign reference product and a Canadian approved innovative product. Preferred foreign reference products are those marketed in a country that formally adopts International Conference on Harmonization (ICH) guidelines and has an approval scheme that is similar to Canada's. Of note, the European Union (EU), which was the fi rst jurisdiction to approve an SEB in 2006, does not permit the use of a foreign reference product.4

Patent Protection

With the Revised Guidance, Health Canada has attempted to allay fears that an SEB manufacturer could circumvent the protections afforded to innovators under the Patented Medicines (Notice of Compliance) Regulations. Th e PM(NOC) Regulations create a framework for pharmaceutical patents to be listed on Health Canada's Patent Register (which is the equivalent of the U.S. "Orange Book") if the patents claim the "medicinal ingredient," or a dosage, formulation or use thereof in respect of a particular drug.

Specifically, the PM(NOC) Regulations are triggered when a "second person" files a drug submission that, directly or indirectly, compares its drug with, or makes reference to, another drug marketed in Canada. Once triggered, the second person must either wait until the expiry of all patents on the Patent Register in respect of the reference product before receiving marketing authorization or send a notice to the "first person" innovator and initiate court proceedings to contest the listed patents.

Clearly, the language of the PM(NOC) Regulations is of concern when a non-Canadian reference product is being considered, because the non-Canadian reference product is not marketed in Canada. Health Canada has proposed revising its PM(NOC) guidance document (PM(NOC) Guidance) to attempt to clarify when an SEB sponsor will be considered a "second person." If a link has been established in a submission between a non-Canadian reference product and a drug authorized for sale in Canada, such submission will be considered to be making a comparison for the purposes of the PM(NOC) Regulations. If the Canadian version of the reference product has patents listed on the Patent Register, the SEB sponsor would be considered a second person, according to Health Canada.

Pure process patents and patents claiming processing intermediates are not listable on the Patent Register. As the authors pointed out in their previous article,5 manufacturing protocol is critical to biologic production, so it is possible that the current listing rules may not sufficiently protect an innovator's intellectual property rights in its biologic product. Th is issue is not discussed in the Revised Guidance or proposed amendment to the PM(NOC) Guidance, and it is unlikely that Health Canada will change its stance on listability requirements.

Data Protection

As discussed, an SEB submission relies in part on data from a previously approved innovative biologic in order to justify a reduced submission package. Concerns relating to data protection were incorporated into the "Data Protection under C.08.004.1 of the Food and Drug Regulations"6 (Guidance on Data Protection). Th is document was first published in draft form on June 25, 2007, and followed by a comment period during which stakeholders were encouraged to provide feedback. Th e final Guidance on Data Protection is effective as of March 30, 2009.

Under the Regulations, an "innovative drug" that contains a medicinal ingredient not previously approved in a drug by Health Canada is entitled to an eight-year term of data protection. This term can be extended for an additional six months for pediatric population submissions. If a subsequent manufacturer seeks approval of its product on the basis of a direct or indirect comparison with an innovative drug marketed in Canada, the manufacturer 1) may not file its drug submission for six years;7 and 2) will not receive marketing authorization for eight years (or eight years and six months) from the date that the innovative drug was approved for sale.

The Guidance on Data Protection indicates that this prohibition will apply to a new drug submission for an SEB where approval is sought on the basis of a comparison to an innovative drug. Furthermore, Health Canada intends to amend the Guidance on Data Protection to confirm that data protection extends to an innovative drug when it is indirectly compared to an SEB by virtue of a foreign reference product. As for patent protection, when a non-Canadian reference biologic is substituted for the Canadian product and a link is established to a drug marketed in Canada, this would be considered a comparison that would trigger the data protection regime.

In their previous article, the authors noted specific concerns regarding the definition of an "innovative drug" in the context of biologics. An innovative drug is characterized by the Regulations as one that "contains a medicinal ingredient not previously approved in a drug by the Minister and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph" (emphasis added). This definition is obviously tailored to traditional small molecule drugs, and Health Canada has provided no guidance on the meaning of "variation" as it pertains to a biologic. It is not therefore clear how this definition would be applied 1) to an SEB, or 2) to an "innovative" biologic developed using a unique production processand containing a medicinal ingredient that is related to, but not identical to, a previously approved biologic.


Several Canadian patents covering biologics have either recently expired or will expire shortly; numerous SEB approvals are thus expected in the coming years. Health Canada has indicated that a number of SEB submissions are pending and so the industry is bracing for the arrival of additional SEBs into the Canadian marketplace.

Although Health Canada made revisions to respond to certain concerns expressed by innovators over the past year, the Revised Guidance falls short in several areas. For example, there is general agreement that the demonstration of similarity will differ depending on the level of complexity and variability that is intrinsic to a particular class of biologic. The need for guidance that is specific to particular categories of SEBs has been repeatedly emphasized, but Health Canada does not intend to formulate such guidance in the near future.8 Th e unique naming of SEBs, a critical component of postmarket surveillance, is also not covered in the Revised Guidance. It is also notable that the degree of similarity that would be required to approve an SEB, and the link required to trigger intellectual property protections where a foreign reference product is used, remains ambiguous.

Health Canada has not proposed a timeline for fi nalizing the Revised Guidance but further consultation with drug manufacturers and nonindustry stakeholders is expected in the coming months.

Ms. Reguly practices intellectual property law in the law firm of Torys LLP, Toronto, Canada.

Ms. McMahon is a Partner in the law firm of Torys LLP, Toronto, Canada. She is the co-chair of the Intellectual Property and Food and Drug Regulatory practices in the firm.


1 C.R.C. c. 870, available at showdoc/cr/C.R.C.-c.870///en?page=1.

2 McMahon, E. & Reguly, T., Follow-on Biologics in Canada: A Look at the New Draft Guidelines, Update, Issue 3, (May/June 2008), 43–45.

3 The Revised Document has been published concurrently with two notices proposing amendments to the guidance documents, titled "Patented Medicines (Notice of Compliance) Regulations" and "Data Protection under C.08.004.1 of the Food and Drug Regulations." These three documents are available at biolog/2009-03-seb-pbu-eng.php.

4 Pending biosimilar bills before the U.S. Senate do not permit the use of a foreign reference product.

5 See note 2, above.

6 Available at prodpharma/applic-demande/guide-ld/data_ donees_protection-eng.php.

7 Note that there is an exception for drug submissions filed under Canada's Access to Medicines Regime, which provides a mechanism for developing countries to receive generic versions of drugs and medical devices at reduced costs.

8 This is in contrast to the practice in the EU, where the European Agency for the Evaluation of Medicinal Products (EMEA) has released guidance documents for several classes of biologics.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.